Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with either manifest hyperkalemia or with a history of hyperkalemia while treated with renin-angiotensin aldosterone system inhibitor (RAASi) therapy. Veltassa® demonstrated a statistically significant difference versus placebo for the primary endpoint to serum potassium levels in a high risk population.
Vifor Pharma Klaus Henning Jensen Nathalie Ponnier Javed Butler Swiss Stock Exchange Vifor Pharma Group
Source: businesswireindia.com